A Comparison of Two Doses of Aspirin (30 mg vs. 283 mg a Day) in Patients after a Transient Ischemic Attack or Minor Ischemic Stroke
- 31 October 1991
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 325 (18), 1261-1266
- https://doi.org/10.1056/nejm199110313251801
Abstract
Aspirin is known to improve the outcome of patients who have had a cerebral transient ischemic attack, but the optimal dose of aspirin remains uncertain. Experimental evidence indicates that 30 mg of aspirin daily alters platelet aggregation more favorably than the 300-mg dose currently used in patients after transient ischemic attack or minor ischemic stroke.This publication has 23 references indexed in Scilit:
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1989
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1988
- The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. The Dutch TIA Study Group.Stroke, 1988
- Secondary prevention of vascular disease by prolonged antiplatelet treatmentBMJ, 1988
- United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim resultsBMJ, 1988
- Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1α excretion in healthy subjectsThrombosis Research, 1987
- Clinical pharmacology of platelet cyclooxygenase inhibition.Circulation, 1985
- "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.Stroke, 1983
- Arachidonic Acid Metabolites and the Interactions between Platelets and Blood-Vessel WallsNew England Journal of Medicine, 1979
- A Randomized Trial of Aspirin and Sulfinpyrazone in Threatened StrokeNew England Journal of Medicine, 1978